

UNITED STATES DISTRICT COURT
WESTERN DISTRICT OF WASHINGTON
AT SEATTLE

IN RE CELL THERAPEUTICS, INC.
CLASS ACTION LITIGATION

CASE NO. 2:10-cv-00414-MJP

ORDER ON MOTION TO DISMISS

This Document Relates to All Actions

The Court, having received and reviewed

1. Motion to Dismiss Consolidated Amended Class Action Complaint for Violation of the Federal Securities Laws (Dkt. No. 57)
2. Lead Plaintiff's Memorandum in Opposition to Defendant's Motion to Dismiss (Dkt. No. 65)
3. Reply in Support of Motion to Dismiss Consolidated Amended Class Action Complaint for Violation of the Federal Securities Laws (Dkt. No. 67)
4. Surreply in Response to Motion to Dismiss Consolidated Amended Class Action Complaint for Violation of the Federal Securities Laws (Dkt. No. 69)

1 and all attached declarations and exhibits, makes the following ruling:

2 IT IS ORDERED that the motion to dismiss Plaintiffs' 10(b) and 10b-5 claims, and their
3 "control person liability" claims, is DENIED.

4 IT IS FURTHER ORDERED that the motion to dismiss the insider trading claim against
5 Defendant James Bianco is DENIED; the insider trading claims against the remaining
6 Defendants will be DISMISSED.

7 IT IS FURTHER ORDERED that Plaintiffs' motion to strike the declarations submitted
8 by Defendants containing statements attributed to the Confidential Witnesses, as well the
9 evidence and argument relating to the increase in Defendant James Bianco's CTI stock holdings
10 during the Class Period (included for the first time in Defendants' reply brief) is GRANTED.

11 **Background**

12 From the Consolidated Amended Class Action Complaint (CAC; Dkt. No. 50):

13 Cell Therapeutics, Inc. (CTI) is a biopharmaceutical company whose primary business is
14 developing new cancer-fighting drugs. ¶ 25. One of the major products in development at the
15 company for the last several years was Pixantrone.

16 In 2004, the Food and Drug Administration (FDA) and CTI entered into a Special
17 Protocol Assessment (SPA). An SPA constitutes an agreement between the FDA and the drug-
18 developing entity (the "sponsor") that, if the sponsor follows the procedure agreed upon in the
19 protocol and the drug proves efficacious, then it will be approved. This bypasses some
20 potentially lengthy and costly procedures for New Drug Applications (NDAs). According to
21 "Guidance for Industry: Special Protocol Assessment, FDA" an SPA can only be modified by
22 written agreement between the FDA and the sponsor and then only if it is intended to improve
23 the study. Failure to follow the agreed-upon protocol constitutes an understanding that the SPA
24

1 is no longer binding. ¶ 27. Documents from Defendants indicate that the company understood
2 this. (“These agreements may not be changed after the clinical studies begin, except in limited
3 circumstances.” 2003 Form 10-K, p. 20; ¶ 62).

4 The SPA contemplated a study using 320 enrollees (¶ 34), but enrollment was slow and
5 by the end of 2007 less than half the required number had been enrolled. ¶¶ 39, 41. CTI made a
6 decision (without agreement by the FDA) to close the study early at 140 enrollees. The decision
7 to close the study was announced on March 25, 2008, but the announcement did not reveal the
8 fact that (1) the study was closing early (i.e., short of the 320-enrollee original goal) and (2) the
9 FDA had not agreed to the modification. ¶ 41. In fact, the 3/25/08 press release stated:

10 The study was conducted under a Special Protocol Assessment from the U.S.
11 Food and Drug Administration (FDA) and Pixantrone has received fast track
12 designation for this indication. (¶ 73)

13 This language (or variations thereof) appeared in every press release Defendants issued
14 during the Class Period. For the next two years, Defendants continued to issue press releases and
15 file public documents which characterized the SPA as still viable and the drug as “fast-tracked”
16 because of it (e.g., “The study received Special Protocol Assessment approval from the U.S.
17 Food and Drug Administration (FDA) in 2004 and Pixantrone has received fast track designation
18 for this indication.” 11/11/08 press release, ¶ 84). Additional statements during that period
19 suggested that the modification of the SPA had been discussed with the FDA (e.g., “We had
20 discussions with the FDA, essentially cutting the enrollment back to a number where we felt
21 would be adequate to still maintain the initial power assumptions in the trial. That was done in
22 about 140 patients.” 12/5/09 earnings call, ¶ 123). At no time during the Class Period was the
23 fact that the modification had not been agreed upon by the FDA revealed.
24

1 From April to June, 2009, CTI began a “rolling” NDA with a goal of achieving approval
2 of Pixantrone for public sale.

3 On February 8, 2010, in anticipation of a meeting between CTI and the Oncologic Drugs
4 Advisory Committee (ODAC) for preliminary review of Pixantrone, the FDA published a
5 Briefing Document which revealed for the first time that the early termination of enrollment in
6 March 2008 had invalidated the SPA. ¶ 125. CTI’s stock dropped 39% in one day. ¶ 128.

7 On March 22, 2010, at the ODAC meeting, it was further revealed that the early
8 termination of the clinical trial had been done without input or agreement from the FDA. ¶ 142.
9 At the conclusion of the meeting, the ODAC voted unanimously that CTI’s clinical trial data was
10 inadequate to support approval of Pixantrone. ¶ 143. CTI stock suffered a one-day drop of 48%.
11 ¶ 144.

12 This class action lawsuit represents the consolidation of a number of separate lawsuits
13 filed against CTI arising out of these circumstances. The CAC alleges violations of securities
14 fraud under § 10(b) of the Exchange Act and SEC Rule 10b-5 against CTI as a corporate entity
15 and against CEO James Bianco, M.D., President Craig Philips, and Executive Vice President
16 Louis Bianco (“the individual Defendants”); and against the individual Defendants for control
17 person liability (under § 20(a) of the Exchange Act and insider trading under § 10(b) and § 20A
18 of the Exchange Act.

19 Discussion

20 Standard of Review

21 For purposes of FRCP 12(b)(6), the Court assumes that the facts plead in the CAC are
22 true. Under § 10(b) of the Securities Exchange Act (15 U.S.C. §§ 78j(b)) and SEC Rule 10b-5
23 (17 C.F.R. § 240.10b-5), Plaintiffs must plead (1) a material misrepresentation or omission; (2)
24

1 scienter; (3) a connection between the misrepresentation or omission and purchase or sale of a
 2 security; (4) reliance; (5) economic loss and (6) loss causation. Stoneridge Inv. Partners, LLC v.
 3 Scientific Atlanta, Inc., 552 U.S. 148, 157 (2008). With the exception of scienter, these elements
 4 are governed by the pleading standards set out in FRCP 8 and 9(b). Plaintiffs are required to
 5 allege “enough factual matter (taken as true)” to suggest that a violation occurred (Bell Atl.
 6 Corp. v. Twombly, 550 U.S. 544, 556 (2007)), drawing all reasonable inferences from the
 7 complaint in Plaintiffs’ favor. *See* Fouad v. Isilon Sys., C07-1764MJP, 2008 WL 5412397, at *2
 8 (W.D.Wash., December 29, 2008).

9 “When there are well-pleaded factual allegations, a court should assume their veracity
 10 and then determine whether they plausibly give rise to an entitlement to relief.” Ashcroft v.
 11 Iqbal, 129 S.Ct. 1937, 1940-41 (2009). Because 10(b) claims sound in fraud, the CAC must
 12 allege the “time, place and specific content of the false representations as well as the identities of
 13 the parties to the misrepresentations” pursuant to FRCP (b). Edwards v. Marin Park, Inc., 356
 14 F.3d 1058, 1066 (9th Cir. 2004).

15 **Plaintiffs’ Claims**

16 **10(b) and 10b-5 violations**

17 Defendants allege three grounds for dismissal of Plaintiffs’ 10(b) and 10b-5 claims: (1)
 18 insufficient allegations of scienter, (2) no proof of loss causation and (3) Defendants’ statements
 19 are protected by the “safe harbor” provisions of the Reform Act.

20 *1. Scienter*

21 Defendants attack the lack of a “smoking gun,” Plaintiffs’ failure to allege a statement
 22 from the FDA to CTI (prior to the 2/8/10 Briefing Document) that “the SPA is invalidated” or
 23 failure to allege any statements from Defendants prior to February 8, 2010 that “we know the
 24

1 SPA is invalid.” But, because direct evidence of scienter is usually only within the knowledge of
 2 the defendants, scienter is often plead and proven on the basis of circumstantial evidence.

3 Maclean v. Huddleston, 459 U.S. 375, 390 n.30 (1983).

4 Not only is the Court required to accept the factual allegations of Plaintiffs’ amended
 5 complaint as true, but the Court’s analysis must be aimed at determining “whether all of the facts
 6 alleged, taken collectively, give rise to a strong inference of scienter, not whether any individual
 7 allegation, scrutinized in isolation, meets that standard.” Tellabs, Inc. v. Makor Issues & Rights,
 8 Ltd., 551 U.S. 308, 322-23 (2007). Defendants attack Plaintiffs’ circumstantial allegations as
 9 being comprised of the kind of evidence which has generally been discredited as adequate to
 10 plead scienter when unaccompanied by specific, direct evidence of fraud. But Plaintiffs’
 11 allegations are not devoid of evidence of specific facts demonstrating the existence of scienter –
 12 which can established through knowledge of falsity or reckless indifference to falsity (In re
 13 Silicon Graphics Inc. Sec. Litig., 183 F.3d 970, 977 (9th Cir. 1999) – and the “aggregate” of
 14 Plaintiffs’ evidence does rise to the level of a “strong inference” of scienter.

15 Two allegations of the CAC comprise particularly strong evidence of scienter. Plaintiffs’
 16 one piece of direct evidence – allegations of a confidential witness (CW 1, described as “a
 17 former Vice President of Clinical Development and Regulatory Affairs at CTI;” ¶ 24(1)) that she
 18 told two of the individual Defendants (the Biancos) that the SPA had been invalidated by their
 19 unilateral actions (¶ 43) – is probably sufficient by itself to support a strong inference of scienter
 20 (at least for those two individual Defendants and the company).

21 The other piece of evidence, albeit circumstantial, which creates a strong inference of
 22 scienter is the language in Defendants’ 10-K forms (e.g., “These agreements may not be changed
 23 after the clinical studies begin, except in limited circumstances.” 2003 Form 10-K, p. 20; ¶ 62).
 24

1 This knowledge is imputable, at a minimum, to the defendant corporation, and gives rise to an
2 inference that the company knew what was required to comply with FDA requirements and that
3 their unilateral deviation from the agreement was not one of the “limited circumstances”
4 permitted; i.e., that CTI had invalidated the SPA.

5 With one exception, the Court does not find that Plaintiffs’ remaining “confidential
6 witness” allegations contribute significantly toward establishing the strong inference of scienter
7 which is their burden. Confidential Witnesses 2, 3 and 4 offer allegations that are, at various
8 points, irrelevant, contradictory and not founded on direct contact or communication with the
9 Defendants. ¶¶ 24, 43, 48, 49.

10 Confidential Witness 5 is a former Assistant Controller, employed throughout the Class
11 Period, who testifies to CTI’s severe financial difficulties (inferring a motive for their alleged
12 concealment of the truth about the SPA). ¶ 39. As with much of Plaintiffs’ circumstantial
13 evidence, facts of this nature can be used to bolster an inference of scienter. *See Howard v.*
14 *Everex Systems, Inc.*, 228 F.3d 1057, 1064 (9th Cir. 2000)(“In particular, the potential alarm
15 signals in the face of Everex's possible financial crisis could cast doubt on Everex's optimistic
16 outlook and support a finding of scienter.”)

17 The remainder of Plaintiffs’ allegations are comprised of circumstantial evidence which
18 Plaintiffs present as either directly supporting an inference of scienter or providing evidence of a
19 motive to engage in fraudulent or reckless misconduct. The evidence covers areas as wide-
20 ranging as Pixantrone’s status as a “core product” of CTI; the Defendants’ executive
21 responsibilities and obligations, their years of experience in the pharmaceutical industry and their
22 “hands-on” management style; the Defendants’ performance-based salary and bonus structure;

1 CTI's desperate financial situation; and the Defendants' stock transactions during the Class
 2 Period. ¶¶ 146-158.

3 The Court finds the latter example unpersuasive. Plaintiffs allege Class Period sales of
 4 2,382,465 shares between all three individual Defendants. This evidence does not support an
 5 inference of scienter. The proper measure of the weight to be accorded this fact lies in the
 6 amount of stock *retained*. See In re Silicon Graphics, 183 F.3d 970, 986 (9th Cir. 1999). The
 7 individual Defendants, after their Class Period sales, retained 73 – 95% of their stock in the
 8 company. Def. Mtn., p. 14. The inference that they were attempting to benefit from their
 9 alleged fraud is weak in the face of retained holdings of that size.

10 Defendants, however, attack the entirety of this evidence as insufficient because of its
 11 circumstantial nature and cite case after case where allegations of the sort discussed above have
 12 been found inadequate to support the “strong inference” of scienter which proper securities fraud
 13 pleading demands. Defendants' argument overlooks two significant points. First, the criticism
 14 leveled at this type of evidence usually focuses on its insufficiency *in and of itself* to create a
 15 proper inference. The cases cited by Defendants often indicate that evidence of this sort, coupled
 16 with “some additional allegation of specific information conveyed to management and related to
 17 the fraud,” can support a strong inference of scienter. Metzler Inv. GMBH v. Corinthian
 18 Colleges, Inc., 540 F.3d 1049, 1068 (9th Cir. 2008). See also In re Hansen Natural Corp. Sec.
 19 Litig., 527 F.Supp. 2d 1142, 1159 (C.D.Cal. 2007)(Plaintiff “*must do more than allege that...*
 20 *key officers had the requisite knowledge by virtue of their ‘hands on’ positions*”); South Ferry
 21 L.P. No. 2 v. Killinger, 542 F.3d 776, 784 (9th Cir. 2008) (“Where a complaint relies on
 22 allegations that management had an important role in the company *but does not contain*
 23
 24

1 *additional detailed allegations about the defendants’ actual exposure to information*, it will
2 usually fall short of the PSLRA standard.”)(all emphasis supplied).

3 Plaintiffs have done more than allege that the individual Defendants were highly-placed
4 corporate executives with a “hands-on” management style who had extensive experience in the
5 pharmaceutical industry and stood to benefit financially if investment funds continued to flow in
6 and FDA milestones were met. They have specifically alleged that two of the Defendants were
7 told that the company’s unilateral modification of the SPA would invalidate it, and they have
8 produced evidence that the company publicly acknowledged that modification of the SPA was
9 impermissible except in limited circumstances. The Court finds that, in light of these specific
10 allegations, the additional allegations of circumstantial evidence do provide strong support to the
11 inference of knowing fraud or reckless misconduct.

12 Second, the Court is mindful of its obligation to look at the totality of the evidence and
13 assess “whether all of the facts alleged, taken collectively, give rise to a strong inference of
14 scienter, not whether any individual allegation, scrutinized in isolation, meets that standard.”
15 Tellabs, 551 U.S. at 322-23. In their totality, the circumstantial and direct facts alleged by the
16 CAC pass the threshold of creating a strong inference of scienter, and the Court has no trouble
17 finding that the inference urged by Plaintiffs from the facts they present is as plausible, and at
18 least as cogent and compelling, as that posited by Defendants.

19
20 2. Loss Causation

21 Plaintiffs’ CAC must be found inadequate unless it provides Defendants with notice of a
22 causal connection between an economic loss and the disclosure of the alleged misrepresentation
23 (between the “corrective disclosure” and the “market reaction”). Metzler Inv. GMBH, 540 F.3d
24

at 1062 (citing Dura Pharmaceuticals, Inc. v. Broudo, 544 U.S. 336, 342 (2005)). There are two “corrective disclosures” – the February 8, 2010 Briefing Document and the March 22, 2010 ODAC findings – and Defendants attack them both as not responsible for the market reactions which followed. The Court undertakes the analysis of this portion of Defendants’ motion cognizant of two factors: (1) loss causation is not subject to a heightened pleading requirement under either the PSLRA or the FRCP (Berson v. Applied Signal Technology, Inc., 527 F.3d 982, 989-990 (9th Cir. 2008)); and (2) as a highly fact-specific issue, determination of loss causation is “generally inappropriate on a motion to dismiss.” In re Gilead Sci. Sec. Litig., 536 F.3d 1049, 1056-1057 (9th Cir. 2008).

a. *February 8, 2010 Briefing Document*

Defendants point out that, in addition to revealing the invalidity of the SPA, this document also raised concerns about the efficacy and the toxicity of Pixantrone. This, they argue, was much more likely the cause of the price drop: while an invalid SPA did not mean certain failure for approval of the drug, efficacy and toxicity concerns would. Defendants also cite the rebound of the stock price (by March 8 it had climbed to a higher value than on February 8) as evidence of no “loss causation” stemming from the news about the SPA.

First of all, “loss causation” is not an “either/or” test. Plaintiffs are only required to allege “a causal connection between the deceptive acts that form the basis for the claim of securities fraud and the injury suffered by the Plaintiff,” and are “not required to show that a misrepresentation was the sole reason for the investment’s decline in value in order to establish loss causation.” In re Daou Systems, Inc., 411, F.3d 1006, 1025 (9th Cir. 2005). The doubts raised regarding efficacy and toxicity may well have contributed to the decline in price, but (drawing every inference in favor of Plaintiffs) it is just as likely that the revelation regarding the

1 invalidity of the SPA (which had clearly been a cornerstone of the Defendants' promotion of
2 their efforts) contributed to the drop, and a finding that both were contributing factors would not
3 entitle Defendants to dismissal.

4 Defendants' argument regarding the price rebound is not persuasive. Loss causation is
5 focused on whether disclosures caused a price drop upon being made known to the market.
6 Assuming that the market responds to new, material information as soon as it becomes publicly
7 available (a permissible assumption under Basic Inc. v. Levinson, 485 U.S. 224, 247 (1988)),
8 Plaintiffs have properly alleged that the drop in CTI's stock price on the day of the February 8
9 disclosure occurred in response to new, material, adverse information. Fluctuations in the price
10 of CTI stock days, weeks or months after the initial drop could be the result of any number of
11 factors and do not invalidate loss causation as plead by Plaintiffs.

12 b. *March 22, 2010 ODAC Findings*

13 Defendants' main point of attack on this allegation is that this "corrective disclosure" did
14 not reveal any new information. Stating information already known to the market cannot create
15 a corrective disclosure. Greenberg v. Crossroads Sys., Inc., 364 F.3d 657, 663 (5th Cir. 2004).
16 This is not a sound argument. There was new information revealed by this disclosure: not only
17 was the SPA invalidated, but it was disclosed for the first time that CTI had *unilaterally*
18 modified the protocol. The "corrective" aspect of this revelation was the public realization that
19 (contrary to the impression created by CTI's press releases), the company had not been working
20 "hand in hand" with the FDA to conduct the Pixantrone clinical trials – its decision to cut off
21 enrollment short of 320 patients had not received FDA approval.

22 Defendants make much of the likely impact of the news that ODAC would recommend to
23 the FDA that Pixantrone not be approved. Unquestionably this was a factor in the stock price
24

1 drop that occurred in the wake of the reports of the ODAC recommendation. However, as
2 discussed above, the Court need only find that Plaintiffs have adequately plead that the news
3 regarding the lack of FDA approval *contributed* to the price drop. The Court agrees with
4 Plaintiffs that their pleadings support that finding.

5 Defendants continue to focus (in their briefing and at oral argument) on the rejection of
6 Pixantrone (both the *potential* for rejection contained in the February 8 disclosure and the
7 *recommendation* for rejection in the March 25 ODAC report) as the more plausible explanation
8 for the market reaction to that information. Defendants' contention ignores two factors regarding
9 the SPA that the Court finds relevant to the ruling regarding of loss causation. The first is the
10 potential for "fast tracking" the approval of Pixantrone that the SPA represented (and which CTI
11 promoted in its press releases; "... and Pixantrone has received fast track designation for this
12 indication;" ¶ 73 *et al.*). It is entirely plausible that the market reacted (at least in part) not just
13 to the news that Pixantrone might not be approved, but to the distinct possibility that (with the
14 invalidation of the SPA) it would not be approved as *quickly*. Drawing every inference in
15 Plaintiffs' favor, the Court finds it reasonable to infer that investors bought CTI stock not just
16 based on the possibility that Pixantrone would be approved, but that because of the SPA it might
17 be approved more quickly than usual, offering a faster return on their investment.

18 The second factor Defendants fail to acknowledge concerns the March 22 ODAC
19 findings. While the findings reiterated the pre-existing information that the SPA had been
20 invalidated, the ODAC report offered new information that the FDA had not approved the
21 modification leading to the SPA's invalidation. This information raised, for the first time, the
22 possibility that CTI had misrepresented or at least mislead the investors by insinuating that the
23 FDA had, for the past two years, *approved* of what they had been doing ("The study received
24

1 Special Protocol Assessment approval from the U.S. Food and Drug Administration (FDA) in
2 2004 and Pixantrone has received fast track designation for this indication.” 11/11/08 press
3 release, ¶ 84). The fact CTI acted unilaterally in modifying (and thus invalidating) the process
4 underlying the SPA was definitely new information and it is not unreasonable to infer the market
5 reacted to the news that the status of the Pixantrone project was not as it had been presented.
6 Investor confidence in the reliability of information being disseminated is unquestionably a
7 factor in corporate goodwill, and also in stock value.

8 Plaintiffs have adequately pled loss causation in connection with both “corrective
9 disclosure” events.

10
11 3. Safe Harbor

12 The “safe harbor” provisions of the Reform Act protect two kinds of statements alleged
13 to be misleading:

- 14
- 15 1. Forward-looking statements accompanied by “meaningful cautionary language”
(15 U.S.C. § 78u-5(c)(1(A)(i)); and
 - 16 2. Forward-looking statements unaccompanied by “meaningful cautionary language” which
17 are made without actual knowledge of their falsity (15 U.S.C. § 78u-5(c)(1(B)(i))

18 Interestingly, Defendants claim that the CAC must be dismissed in its entirety because
19 “most” of the statements alleged to be false or misleading are protected by these safe harbor
20 provisions. Def. Mtn., p. 19. Defendants fail to explain how, if some of the statements are not
21 protected, they are still entitled to dismissal.

22 The Court finds a sufficient number of statements are not protected by the safe harbor
23 provisions and Defendants are not entitled to dismissal on this basis. Defendants focus on the
24

1 | cautionary language concerning the perils of new drug approval in every filing or press release.
2 | All the statements about the progress of the Pixantrone trials and the company's hopes for
3 | approval are properly characterized as "forward-looking" and there is adequate language about
4 | "no guarantees" to constitute "meaningful caution," but Defendants' argument misses the point
5 | of Plaintiffs' complaint regarding the SPA.

6 | The continual references, throughout the Class Period, to the SPA (including the
7 | representation that the study was being conducted "under the SPA" and that the drug had been
8 | fast-tracked "because of this indication") were not "forward-looking" statements – they referred
9 | to what Defendants were alleging as present facts: i.e., the ongoing conduct of the clinical trials
10 | for Pixantrone and the "fast-track" nature of the approval process by virtue of the SPA
11 | agreement. What Plaintiffs are complaining about is being misled into believing the SPA was in
12 | effect throughout the Class Period when in fact it had been invalidated as of March 25, 2008.
13 | Misrepresentations of that nature do not qualify for "safe harbor" immunization.

14 | Having said that, the Court finds that the only statements to which this "present fact"
15 | analysis applies are the press releases during the Class Period (3/25/08, ¶¶ 71-73; 11/23/08, ¶ 79;
16 | 11/11/08, ¶84; 1/27/09, ¶ 86; 1/28/09, ¶88; 2/10/09, ¶92; 2/18/09, ¶96; 4/14/09, ¶106; 9/16/09,
17 | ¶117; 2/9/10, ¶¶ 130-132) and the earnings call of 12/5/09 (¶ 123: "We had discussion with the
18 | FDA, essentially cutting the enrollment back to a number where we felt would be adequate to
19 | still maintain the initial power assumptions in the trial;" Defendant. J. Bianco). The SEC filings
20 | (primarily Form 10-K's) are devoid of any representations regarding the SPA, and are replete
21 | with cautionary language. But, as long as the "strong inference" of scienter regarding
22 | Defendants' knowledge of the invalidation of the SPA remains standing, the press release
23 |
24 |

1 statements stand as more than adequate allegations of dissembling on Defendants' part and
2 Plaintiffs are entitled to prevail on the motion to dismiss their 10(b) and 10b-5 claims.

3
4 Control Person Liability

5 Defendants' argument for dismissal of the § 20(a) "control person liability" claims is
6 premised on their prevailing on their motion to dismiss the underlying 10(b) and 10b-5 claims.
7 Having found for Plaintiffs on that portion of the motion, the Court finds that "control person
8 liability" has been adequately alleged.

9
10 Insider Trading

11 Defendants seek dismissal of these claims based on Plaintiffs' failure to allege
12 "contemporaneous trading" by any of the Lead Plaintiffs. Contemporaneous trading must be
13 pled with particularity in accordance with FRCP 9(b) and is subject to the PSLRA's heightened
14 pleading standards. Beubronner v. Milken, 6 F.3d 666, 670 (9th Cir. 1993). The CAC does not
15 allege the dates on which the Lead Plaintiffs purchased CTI common stock (only pleads
16 conclusorily that the purchase was contemporaneous; ¶ 189). The accompanying certifications
17 of stock purchases (exhibits to the CAC) plead purchases three days to four months after the
18 alleged "suspicious sales." CAC, Exh's A-C.

19 Plaintiffs' response is that the stock purchase by Plaintiff Shah was within 2 business
20 days of Defendant J. Bianco's stock sale, and cites unpublished District Court opinions finding
21 trades within four days of the sale to be contemporaneous. In re Novatel Wireless Sec. Litig.,
22 2010 U.S. Dist. LEXIS 49543, at *25-26 (S.D.Cal. May 12, 2010). Defendants cite District
23 Court cases from several jurisdictions (including the Ninth Circuit) for the proposition that
24

1 “[w]hen a company’s stock is regularly traded... the shareholder must purchase his shares on the
2 *same day* or *one day* after the allegedly suspicious sale to have § 20A standing.” Reply, p. 12
3 (emphasis in original). See In re Countrywide Fin. Corp. Sec. Litig., 588 F.Supp.2d 1132, 1204-
4 05 (C.D.Cal. 2008); In re Fed. Nat’l Mortg. Ass’n Sec. Deriv. & ‘ERISA’ Litig., 503 F.Supp.2d
5 25, 46-48 (D.D.C. 2007); In re MicroStrategy, Inc. Sec. Litig., 115 F.Supp.2d 620, 664 (E.D.Va.
6 2000).

7 None of this constitutes binding precedent. The Court finds that there is currently no
8 Ninth Circuit definition of “contemporaneous” as applied to § 20A insider trading, and that two
9 business days is sufficiently close in time to satisfy the term.

10 However, this finding only applies to Defendant James Bianco. There are no allegations
11 of purchases by Plaintiffs related to sales of stock by any of the other Defendants. Accordingly,
12 the claim will remain against James Bianco and be dismissed against the remaining Defendants.

14 Conclusion

15 Looked at in their totality, the allegations by Plaintiffs in their CAC create a “strong
16 inference” of scienter which is at least as cogent and compelling as the inference urged by
17 Defendants. Plaintiffs have adequately pled loss causation regarding both “corrective
18 disclosures.” None of Defendants’ statements (except their SEC filings) are entitled to “safe
19 harbor” protection.

20 “Control person liability” has been sufficiently alleged based on the allegations of 10(b)
21 and 10b-5 violations. The claim for insider trading alleged against Defendant James Bianco will
22 remain; the insider trading claims against the other Defendants will be dismissed.

1 The clerk is ordered to provide copies of this order to all counsel.

2 Dated February _4_, 2011.

3
4 

5 Marsha J. Pechman
6 United States District Judge
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24